JP2015502135A - 多発性硬化症の治療のためのａｐｃ媒介寛容誘導 - Google Patents

多発性硬化症の治療のためのａｐｃ媒介寛容誘導 Download PDF

Info

Publication number
JP2015502135A
JP2015502135A JP2014532366A JP2014532366A JP2015502135A JP 2015502135 A JP2015502135 A JP 2015502135A JP 2014532366 A JP2014532366 A JP 2014532366A JP 2014532366 A JP2014532366 A JP 2014532366A JP 2015502135 A JP2015502135 A JP 2015502135A
Authority
JP
Japan
Prior art keywords
cells
nucleic acid
protein
multiple sclerosis
mog
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014532366A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015502135A5 (enExample
Inventor
ドレーシュ，クリスティアン
アンドラーデ ペレイラ，ブルーナ デ
アンドラーデ ペレイラ，ブルーナ デ
アッカーマン，マティアス
フラーフェル，コーネル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zurich Universität
Original Assignee
Zurich Universität
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zurich Universität filed Critical Zurich Universität
Publication of JP2015502135A publication Critical patent/JP2015502135A/ja
Publication of JP2015502135A5 publication Critical patent/JP2015502135A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2014532366A 2011-09-26 2012-09-26 多発性硬化症の治療のためのａｐｃ媒介寛容誘導 Pending JP2015502135A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP11182700.2 2011-09-26
EP11182700 2011-09-26
US61/573,200 2011-11-14
PCT/EP2012/068954 WO2013045488A1 (en) 2011-09-26 2012-09-26 Apc-mediated tolerance induction for therapy of multiple sclerosis

Publications (2)

Publication Number Publication Date
JP2015502135A true JP2015502135A (ja) 2015-01-22
JP2015502135A5 JP2015502135A5 (enExample) 2015-11-19

Family

ID=46924448

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014532366A Pending JP2015502135A (ja) 2011-09-26 2012-09-26 多発性硬化症の治療のためのａｐｃ媒介寛容誘導

Country Status (6)

Country Link
US (1) US9592259B2 (enExample)
EP (1) EP2760478A1 (enExample)
JP (1) JP2015502135A (enExample)
KR (1) KR20140116054A (enExample)
CN (1) CN104010664A (enExample)
WO (1) WO2013045488A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014210540A1 (en) * 2013-06-28 2014-12-31 Baylor Research Institute Dendritic cell asgpr targeting immunotherapeutics for multiple sclerosis
JP6646282B2 (ja) * 2014-04-24 2020-02-14 ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド 多発性硬化症のためのａａｖ系遺伝子療法
US12485186B2 (en) 2017-03-31 2025-12-02 The Children's Medical Center Corporation Antibody-mediated conditioning with immunosuppression to enable allogeneic transplantation
CA3142487A1 (en) * 2019-06-04 2020-12-10 Thomas Jefferson University Oligodendrocyte-derived extracellular vesicles for therapy of multiple sclerosis
CN111089972B (zh) * 2019-12-18 2021-05-14 天津天海新域生物科技有限公司 一种用于检测抗人体髓鞘碱性蛋白抗体的试剂盒及其应用
EP4135777A4 (en) 2020-04-14 2025-03-12 University Of Florida Research Foundation, Incorporated AAV-BASED GENE THERAPIES FOR THE TREATMENT OF AUTOIMMUNE DISEASES
WO2023240274A1 (en) * 2022-06-10 2023-12-14 The Medical College Of Wisconsin, Inc. Immune tolerance induction for auto-immune diseases through platelet targeted gene therapy involving myelin oligodendrocyte glycoprotein (mog) polypeptide.
CN116200414B (zh) * 2022-08-31 2024-10-18 天津华科泰生物技术有限公司 一种重组人髓鞘少突胶质细胞糖蛋白及其制备方法和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004525909A (ja) * 2001-03-05 2004-08-26 スラビン、シモン 脱灰骨基質及び／又は石灰化骨基質と共に骨髄細胞を含む組成物並びに骨髄移植におけるその使用
JP2004535364A (ja) * 2001-01-26 2004-11-25 エモリー・ユニバーシティ 臓器移植の免疫寛容を誘発し、異常血色素症を処置する方法
JP2008061622A (ja) * 2006-09-11 2008-03-21 Mitsubishi Kagaku Iatron Inc 造血幹細胞移植療法の施行患者の病態把握方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7090982B2 (en) * 1991-10-22 2006-08-15 The Governors Of The University Of Alberta Methods of predicting therapeutic efficacy of treatment of a multiple sclerosis patient
US20030049797A1 (en) * 2001-04-16 2003-03-13 Yoshikazu Yuki Hybrid proteins for autoimmune disease
SG183012A1 (en) * 2004-06-04 2012-08-30 Genentech Inc Method for treating multiple sclerosis
AU2006304274B2 (en) * 2005-10-13 2012-08-16 Celularity Inc. Production of oligodendrocytes from placenta-derived stem cells
US8188218B2 (en) * 2006-10-27 2012-05-29 University Of Kansas Bi-functional peptides for multiple sclerosis treatment and diagnosis
US8673286B2 (en) 2007-04-09 2014-03-18 Northwestern University DOPA-functionalized, branched, poly(aklylene oxide) adhesives
DE102007039429A1 (de) * 2007-08-21 2009-02-26 Imtm Gmbh Verfahren zur Aktivierung regulatorischer T-Zellen
KR101103423B1 (ko) 2009-09-04 2012-01-06 아주대학교산학협력단 생체 주입형 조직 접착성 하이드로젤 및 이의 생의학적 용도
US20130053594A1 (en) 2009-12-17 2013-02-28 The University Of Chicago Methods of making self-healing polymer and gel compositions

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004535364A (ja) * 2001-01-26 2004-11-25 エモリー・ユニバーシティ 臓器移植の免疫寛容を誘発し、異常血色素症を処置する方法
JP2004525909A (ja) * 2001-03-05 2004-08-26 スラビン、シモン 脱灰骨基質及び／又は石灰化骨基質と共に骨髄細胞を含む組成物並びに骨髄移植におけるその使用
JP2008061622A (ja) * 2006-09-11 2008-03-21 Mitsubishi Kagaku Iatron Inc 造血幹細胞移植療法の施行患者の病態把握方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
AUTOIMMUNITY,2011,44(3),P.177-87,EPUB-2010-OCT-1, JPN6016031329, ISSN: 0003382366 *
J.IMMUNOL.,2008,181(7),P.4495-506, JPN6016031331, ISSN: 0003382367 *

Also Published As

Publication number Publication date
KR20140116054A (ko) 2014-10-01
US9592259B2 (en) 2017-03-14
US20140242037A1 (en) 2014-08-28
WO2013045488A1 (en) 2013-04-04
EP2760478A1 (en) 2014-08-06
CN104010664A (zh) 2014-08-27

Similar Documents

Publication Publication Date Title
Marín et al. Tolerogenic dendritic cells in solid organ transplantation: where do we stand?
US9592259B2 (en) APC-mediated tolerance induction for therapy of multiple sclerosis
US9018006B2 (en) Stable Tregs and related materials and methods
Raimondi et al. Mammalian target of rapamycin inhibition and alloantigen-specific regulatory T cells synergize to promote long-term graft survival in immunocompetent recipients
US20080311140A1 (en) Antigen specific immunosuppression by dendritic cell therapy
JP2019511244A (ja) 操作された抗原提示細胞及びそれらの使用
JP2014193881A (ja) 併用療法におけるｃｄ８３の使用
US20140219979A1 (en) Hsp60, hsp60 peptides and t cell vaccines for immunomodulation
Koga et al. IL10-and IL35-secreting MutuDC lines act in cooperation to inhibit memory T cell activation through LAG-3 expression
JP2020055844A (ja) 単離されたドナーｍｈｃ由来ペプチド及びその使用
US20210147801A1 (en) Methods for increasing expansion and immunosuppressive capacity of a population of cd8+cd45rclow/- tregs
Saha et al. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen
JP2020055845A (ja) 単離されたドナーｍｈｃ由来ペプチド及びその使用
EP4340948A1 (en) Synthetic protein for inducing immune tolerance
Ha et al. Transplantation of mouse HSCs genetically modified to express a CD4-restricted TCR results in long-term immunity that destroys tumors and initiates spontaneous autoimmunity
US20220387517A1 (en) Fibroblast therapy for inflammatory bowel disease
WO2017214190A1 (en) Engineered dendritic cells that express 1a-hydroxylase and uses thereof for treating immune-mediated diseases
EP1589030A1 (en) Bob-1 specific T cells and methods to use
EP3958887B1 (en) Medical uses for inducing or restoring immune tolerance
JP2017533238A (ja) 抗原特異的寛容のための組成物及び方法
US20120114681A1 (en) Use of specific peptides in the preparation of a medicament for the treatment of monoclonal gammopathy of undetermined significance (mgus) or of smoldering multiple myeloma (smm)
Lahl Control of immune responses towards self and non-self by Foxp3+ regulatory T cells
Ha CD4+ T cell mediated tumor immunity following transplantation of TRP-1 TCR gene modified hematopoietic stem cells
Li CD24 in T lymphocyte homeostatic proliferation and autoimmune disease
Curran Expansion of antigen specific regulatory T cells in an IDO expressing fibroblast co-culture

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150925

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150928

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160824

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161124

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170208